Batatasin III

ID: batatasin_iii

Aliases: Batatasin-III, Dendrobium stilbenoid, bibenzyl stilbene

Type: compound

Route/form: no established human route; preclinical/research compound context

Status: research_compound

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 4

Broad outcomes: Gut / immune / inflammation, Pain / addiction / acute care

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• gut microbiota-gut-brain axis
• NLRP3-IL-1beta inflammatory pathway
• enteric neurotransmitter signaling

Optimization domains

• gut health
• microbiome
• constipation
• motility
• inflammation
• pain
• natural product

Research basis

• A loperamide-induced slow-transit constipation mouse study reports improved transit, fecal parameters, inflammatory markers, neurotransmitter readouts, and 16S microbiota shifts.
• Additional Batatasin III pharmacology literature supports it as a bioactive Dendrobium stilbenoid with CNS/pain and anti-inflammatory relevance.

Limits, risks, and missing evidence

• No human constipation outcome data are established, and Dendrobium extracts are not equivalent to purified Batatasin III.
• The loperamide mouse model is useful for mechanism but weak for dose, product, and chronic-use translation.

Risk flags

• preclinical only
• research compound
• botanical extract not equivalent
• dose translation uncertain
• limited safety data

Linked papers, labels, and reviews

1. Batatasin III alleviates slow transit constipation by regulating gut microbiota and inhibiting the NLRP3-IL-1beta pathway
   preclinical / pubmed_batatasin_constipation_microbiota_2025
   Loperamide-induced slow-transit constipation mouse study using transit, fecal, inflammatory, neurotransmitter, and 16S microbiome endpoints.
2. Batatasin III, a Constituent of Dendrobium scabrilingue, Improves Murine Pain-like Behaviors with a Favorable CNS Safety Profile
   preclinical / pubmed_batatasin_pain_cns_mouse_2022
   Mouse Batatasin III pharmacology source; supports broader bioactivity and CNS/pain safety context, not constipation efficacy.
3. Design, Synthesis, anti-inflammatory activity Evaluation, preliminary exploration of the Mechanism, molecule Docking, and structure-activity relationship analysis of batatasin III analogs
   preclinical / pubmed_batatasin_analogs_inflammation_2023
   Batatasin III analog anti-inflammatory pharmacology and SAR source for inflammatory-mechanism plausibility.
4. Therapeutic potential of the chemical composition of Dendrobium nobile Lindl
   review / pubmed_dendrobium_nobile_chemistry_review_2023
   Dendrobium chemistry and pharmacology review that lists Batatasin III among constituent bibenzyl/stilbenoid compounds.